Scarica l'app Stockscreener
1.835
1.66%
0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.81
Aprire:
$1.81
Volume 24 ore:
604.11K
Relative Volume:
0.76
Capitalizzazione di mercato:
$78.27M
Reddito:
$55,200
Utile/perdita netta:
$-21.24M
Rapporto P/E:
-3.1181
EPS:
-0.5885
Flusso di cassa netto:
$-19.37M
1 W Prestazione:
-9.36%
1M Prestazione:
+8.24%
6M Prestazione:
-23.65%
1 anno Prestazione:
+15.00%
Intervallo 1D:
$1.7201
$1.84
Intervallo di 1 settimana:
$1.7201
$2.145
Portata 52W:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.835 | 77.20M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug - Investing.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial - Investing.com
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial By Investing.com - Investing.com India
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - The Manila Times
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease - Moomoo
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics, Inc. Announces 2026 Shareholder Vote Results and Emerging Growth Company Status (GANX) - Minichart
Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX) - TradingView
Gain Therapeutics Shareholders Confirm Board and Auditor Choices - TipRanks
Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting - Stock Titan
GANX Forecast — Price Target — Prediction for 2027 - TradingView
3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research - Sahm
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
Gain Therapeutics Inc (GANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gain Therapeutics Inc (GANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics, Inc. (VKTX) gains as market dips: What you should know - MSN
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - Yahoo Finance
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Guidance Range - newsline.com
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Biotech Gain Therapeutics joins H.C. Wainwright Neuro expert summit - Stock Titan
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.18%
2.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):